According to PwC, the counterfeit drug market is worth over $200 billion per annum. In recent months the pharmaceutical industry has taken huge steps to tackle the rising problem of falsified medicines with the introduction of serialisation regulations in more than 50 countries worldwide.
A more globally aligned strategy to combat counterfeiting would be beneficial, but with the varying regulations in different markets, the industry is some way to achieving this.
In this article with PharmaVOICE, Staffan Widengren, director of corporate projects at Recipharm discusses the global track & trace regulations that are being put in place and highlights some examples of best practice within the industry. He also talks about some of the key differences in serialisation legislation and why this adds complexity for manufacturers supplying to multiple markets.
Read the full article here: